US OptionsDetailed Quotes

BBIO241220P25000

Watchlist

0.13
+0.03+30.00%

15min DelayClose Dec 13 16:00 ET

0.13High0.10Low

BridgeBio Pharma Stock Discussion

leo1212

Dec 10 07:23

$BridgeBio Pharma (BBIO.US)$ gt news?

103346747

Nov 26 04:35

$BridgeBio Pharma (BBIO.US)$ Buy Now it's flying up to 35

102539778

Nov 26 03:50

$BridgeBio Pharma (BBIO.US)$ ready for more boomboom candles

Meltyy

Nov 26 01:17

🚨 1 PDUFA this week!

See FDA PDUFA update 👇
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...

Clintzilla

Nov 25 08:36

$BridgeBio Pharma (BBIO.US)$ woot woot, watch FBIO and them for sympathy

Jaguar8

Nov 24 20:46

MY MONDAY WATCHLIST. These are the stocks with POSSIBLE run between 20% and up based on news, chart, or promotion.

NOTE: NFA. Do not open position without buy pressure, volume. Check indicators, chart.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...

Quantum Computing Boom: How Tech Giants are disrupting the AI industry?

Jaguar8

Nov 22 19:28

Definitely on watch Monday. FDA approval for reducing cardiovascular death & hospitalizations. Will receive $500M as royalty funding agreement. Bayer granted rights to commercialize in Europe. BIG!

$BridgeBio Pharma (BBIO.US)$

Jaguar8

Nov 22 19:06

NEWS

$BridgeBio Pharma (BBIO.US)$
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
BridgeBio Pharma announced FDA approval of Attruby™ (acoramidis) for treating adults with ATTR-CM to reduce cardiovascular death and hospitalization.
The approval is based on the ATTRibute-CM Phase 3 study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovasc...

Trytosaveabit

Nov 22 18:42

T 1 News Halt!

$BridgeBio Pharma (BBIO.US)$ Reuters
28 mins ago
Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients
BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement
BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe

Stock_Drift

Feb 2 04:12

$AstraZeneca (AZN.US)$ $BridgeBio Pharma (BBIO.US)$ $ASTRAZENECA PLC (AZNCF.US)$
📊⚡️📊

AstraZeneca's Results From Japan Phase 3 Trial Of Acoramidis For Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Is Consistent With BridgeBio Pharma's ATTRibute-CM Phase 3 Trial, Including Survival, Cardiac-Related Hospitalizations

No comment yet